Pioneering the development
of engineered IgM antibodies
NEWS
PRESENTATIONS & PUBLICATIONS
SITC Poster: IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion
SITC 2021 – The Society for Immunotherapy of Cancer 36th Annual Meeting & Pre-Conference Programs November 12-14, 2021 Thierry D. Giffon; Melanie Desbois; Dean Ng, Ph.D.; Poonam…
SITC Abstract: IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion
SITC 2021 – The Society for Immunotherapy of Cancer 36th Annual Meeting & Pre-Conference Programs November 12-14, 2021 Thierry D. Giffon; Melanie Desbois; Dean Ng, Ph.D.; Poonam…
Multimeric IgM Antibodies Targeting DR5 are Potent and Rapid Inducers of Tumor Cell Apoptosis In Vitro and In Vivo
PEGS Europe, Barcelona, Spain – November 4, 2021 Angus M. Sinclair, PhD, Vice President, Immuno-oncology Research IGM Biosciences, Inc., 325 E Middlefield Road, Mountain View, CA 94043 Sinclair-et-al-PEGS-EU-2021
Abstract #132: A Phase 1 Dose Escalation Study of IGM-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies
The 63rd ASH Annual Meeting and Exposition – December 11-14, 2021
Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199
Published in Molecular Cancer Therapeutics, October 28, 2021 Authors: Beatrice T. Wang, Tasnim Kothambawala, Ling Wang, Thomas J. Matthew, Susan E. Calhoun, Avneesh K. Saini, Maya F. Kotturi,…
In the Media: An IgM antibody platform to tackle SARS-CoV-2 and its variants
Published in Drug Target Review.
Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants
Published in Nature, 03 June 2021 Citation: Ku, Z., Xie, X., Hinton, P.R. et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature (2021)…
Pharmacodynamic Assessment of an IgM Antibody Using BRGSF-HIS Mice
Predict Innovation — May 20, 2021
Next-Generation Approaches to COVID-19 Therapeutics: Clinical Challenges and Engineering Solutions
PEGS Boston – May 11-13, 2021 Session: Novel and Alternative Approaches to Developing Covid-19 Therapeutics – May 11, 2021
Engineering the Future: Next Gen Platforms in Oncology
Cancer Progress Virtual – May 4-6, 2021 Keynote Address – May 4, 2021